AURORA, Colo., Aug. 17, 2023 /PRNewswire/ — Foresight Diagnostics, a number one supplier of ultrasensitive most cancers detection checks, nowadays introduced the appointment of John Truesdell as Leader Industry Officer.
John involves Foresight maximum just lately from SeQure Dx, the place he served as Leader Industry Officer. Previous to this, he held quite a lot of management roles at Basis Medication, riding the improvement and commercialization of pioneering NGS spouse diagnostic platforms that supported dozens of groundbreaking oncology drug launches. Moreover, John has held numerous industrial roles at Boston Medical and Semprus Biosciences (now a part of Teleflex).
“John’s breadth of business management revel in inside this house make him a super addition to the Foresight Group,” mentioned Jake Chabon, CEO of Foresight Diagnostics. “His previous good fortune figuring out and commercializing scientific genomic packages and spouse diagnostics partnerships make him well-suited to our objective of advancing Foresight’s generation and giving sufferers, suppliers, and companions get right of entry to to our ultra-sensitive MRD assays. We’re happy to have him on board.”
Along with his company revel in, John is an army veteran who served over a decade international as a US Military SEAL. He holds an MBA from MIT Sloan Faculty of Control, an MS from Harvard-MIT Department of Well being Sciences and Era and a BA in Biochemistry and Molecular, Mobile and Developmental Biology from the College of Colorado Boulder.
“I’m overjoyed to sign up for Foresight Diagnostics as Leader Industry Officer,” mentioned John Truesdell. “My occupation has been devoted to advancing healthcare answers that fortify affected person results and I sit up for running with the Foresight group to pressure common adoption of our best-in-class MRD assays. Now we have a fantastic alternative with Foresight’s ultrasensitive most cancers recurrence detection generation to make a significant distinction in how most cancers is monitored and handled, and I’m excited to steer the price to get it into the arms of companions and suppliers to advance the usual of care.”
About Foresight Diagnostics
Foresight Diagnostics is a privately held most cancers diagnostics corporate and CLIA-registered laboratory. The corporate has advanced a singular liquid biopsy checking out platform for the size of minimum residual illness (MRD) this is considerably extra touchy (with a detection restrict underneath 0.0001%, or one part-per-million) than present checks. The enhanced sensitivity of the Foresight lymphoma MRD assay may give actionable knowledge to physicians and biopharmaceutical firms to permit extra customized remedy approaches for sufferers with B-cell malignancies. Foresight is creating an MRD assay for different tumor sorts in accordance with the similar generation. For more info, please consult with foresight-dx.com and observe us on Twitter and LinkedIn.
About PhasED-Seq
The Foresight MRD platform is in accordance with the Phased variant Enrichment and Detection via Sequencing (PhasED-Seq) generation. PhasED-Seq lowers the mistake profile of mutation detection in sequencing information via requiring the concordant detection of 2 separate non-reference occasions in a person DNA molecule. Through detecting a couple of mutation, PhasED-Seq can extra as it should be distinguish tumor-derived mobile loose DNA (i.e., ctDNA) from wholesome mobile loose DNA – enabling detection of ctDNA at ranges underneath one part-per-million (<0.0001%). PhasED-Seq has been widely validated in masses of sufferers with B-cell lymphomas.
Media touch knowledge
E-mail: [email protected]
Telephone: 720-443-3658
SOURCE Foresight Diagnostics
